| Literature DB >> 29632815 |
Tianyi Ma1,2,3, Mi-Jeong Yoo2, Tong Zhang2, Lihong Liu2, Jin Koh4, Wen-Yuan Song5,6, Alice C Harmon2,6, Wei Sha1,3, Sixue Chen2,4,6.
Abstract
Sucrose nonfermenting 1-related protein kinase 2.6 (SnRK2.6), also known as Open Stomata 1 (OST1) in Arabidopsis thaliana, plays a pivotal role in abscisic acid (ABA)-mediated stomatal closure. Four SnRK2.6 paralogs were identified in the Brassica napus genome in our previous work. Here we studied one of the paralogs, BnSnRK2.6-2C, which was transcriptionally induced by ABA in guard cells. Recombinant BnSnRK2.6-2C exhibited autophosphorylation activity and its phosphorylation sites were mapped. The autophosphorylation activity was inhibited by S-nitrosoglutathione (GSNO) and by oxidized glutathione (GSSG), and the inhibition was reversed by reductants. Using monobromobimane (mBBr) labeling, we demonstrated a dose-dependent modification of BnSnRK2.6-2C by GSNO. Furthermore, mass spectrometry analysis revealed previously uncharacterized thiol-based modifications including glutathionylation and sulfonic acid formation. Of the six cysteine residues in BnSnRK2.6-2C, C159 was found to have different types of thiol modifications, suggesting its high redox sensitivity and versatility. In addition, mBBr labeling on tyrosine residues was identified. Collectively, these data provide detailed biochemical characterization of redox-induced modifications and changes of the BnSnRK2.6-2C activity.Entities:
Keywords: BnSnRK2.6‐2C; mass spectrometry; monobromobimane; phosphorylation; redox regulation; thiol modification
Year: 2018 PMID: 29632815 PMCID: PMC5881534 DOI: 10.1002/2211-5463.12401
Source DB: PubMed Journal: FEBS Open Bio ISSN: 2211-5463 Impact factor: 2.693
Figure 1Structural analysis of BnSnRK2.6‐2C. (A) Conserved domains of BnSnRK2.6‐2C. A serine/threonine protein kinase domain with activation loop, a SnRK2‐specific domain (Domain I) and a SnRK2, group III‐specific domain (Domain II) were predicted. (B) Comparison of amino acids sequences of BnSnRK2.6‐2C and AtOST1 (At4g33950). Sequences of conserved domains are shown in boxes, and locations of cysteine residues are labeled in red. (C) Prediction of the tertiary structure of BnSnRK2.6‐2C. Different secondary structures are shown in cartoon, and domains are shown in different colors (i); cysteine residues and thiol groups are labeled in (ii) to (vi).
Figure 2Autophosphorylation and redox regulation of recombinant BnSnRK2.6‐2C. (A) Expression and purification of recombinant BnSnRK2.6‐2C. Empty pET28a vector was used as control. (B) Peptides and phosphorylation sites of BnSnRK2.6‐2C identified by LC‐MS/MS. Sequences of peptides identified are shown in orange, and phosphorylation sites identified are shown in blue with underlines. The serine/threonine protein kinase domain is shaded in gray with the activation loop shaded in yellow. (C) Autophosphorylation activity of BnSnRK2.6‐2C treated with GSNO and/or DTT. Upper panel: autoradiograph of BnSnRK2.6‐2C. Lower panel: Coomassie Blue staining as loading control. (D) Autophosphorylation activity of BnSnRK2.6‐2C treated with GSSG and/or GSH with glutaredoxin or DTT. Upper panel: autoradiograph of BnSnRK2.6‐2C. Lower panel: Coomassie Blue staining as loading control.
Figure 3Reversible cysteine thiol oxidation occurred in BnSnRK2.6‐2C treated with GSNO or GSSG. (A) Forward mBBr labeling strategy workflow for detecting reversible cysteine thiol oxidation. Treatment of proteins with oxidants resulted in oxidation of some sulfhydryl groups (triangles or squares). Following removal of the oxidant, mBBr was used to label the free thiols (SH). Alternatively, the protein was treated with reductant, and some oxidized sulfhydryls (triangles) were returned to the reduced state (SH), while others remained blocked (squares). Subsequent treatment of protein with mBBr resulted in the modification of sulfhydryls by the reagent, and proteins with mBBr modifications appeared as fluorescent bands on UV‐illuminated gels. Reversible cysteine thiol oxidation occurred in BnSnRK2.6‐2C treated with GSNO (B) or GSSG (C). Upper panel: UV fluorescence of mBBr‐labeled BnSnRK2.6‐2C. Lower panel: Coomassie Blue staining as loading control. Relative quantification of mBBr fluorescence of BnSnRK2.6‐2C treated with GSNO (D) or GSSG (E). Fluorescence was determined by fluorescence intensity divided by the intensity of Coomassie Blue stain calculated by ImageJ software; values of 0 mm GSNO and 0 mm GSSG treatments were normalized as 1, respectively. Three replicates were used for statistical analysis, Duncan method was used in one‐way ANOVA analysis, P < 0.05, and standard errors were indicated.
Overview of peptides with cysteine thiol modifications in different redox treatments. The percentage in parenthesis represents the fraction of peptide spectral matches (PSMs) of the peptides containing modified cysteine residues relative to the total PSMs of BnSnRK2.6‐2C. Positive control: The protein was reduced with DTT, labeled with mBBr directly, and then treated with IAM. Negative control: DTT‐reduced free thiols were blocked with IAM before the mBBr labeling. DTT control: The protein was blocked with IAM, then reduced with DTT and labeled with mBBr. GSH control: The protein was blocked with IAM and then reduced with GSH and Grx, followed by mBBr labeling. GSNO, GSSG, and GSSG + GSH treatments (reverse labeling): After the treatment, IAM was used to block the remaining free thiol groups. Reversibly oxidized cysteine residues were then reduced with DTT or GSH and Grx, followed by mBBr labeling
| Positive control | Negative control | DTT control | GSH control | GSNO treatment | GSSG treatment | GSSG + GSH treatment | |
|---|---|---|---|---|---|---|---|
| IAM | C159 (0.21%) |
C107 (0.57%) |
C107 (0.25%) |
C107 (0.07%) |
C107 (0.18%) |
C159 (5.32%) |
C159 (5.75%) |
| mBBr |
C107 (0.53%) | C159 (0.20%) | C159 (0.60%) | C159 (0.57%) |
C131 (0.11%) |
C131 (0.20%) | |
| Glutathionylation | C159 (0.27%) |
C107 (0.30%) | C159 (1.27%) |
C159 (0.63%) | |||
| Sulfinic/sulfonic acid | C159 (0.07%) | C159 (0.13%) | C159 (0.50%) | C159 (0.39%) | C159 (0.38%) | C159 (0.42%) | C159 (0.17%) |
Numbers in brackets are percentages of the PSMs of peptides containing modified cysteine residues over the total PSMs of the recombinant BnSnRK2.6‐2C in different treatments.
Indicates cysteine‐containing peptides detected by LC‐MS/MS but the quality of MS2 spectra was of relatively low confidence. All the data represent average of four replicates.
Figure 4Multiple cysteine thiol modifications detected on C159 of BnSnRK2.6‐2C by LC‐MS/MS. MS/MS spectra of peptides containing C159 of BnSnRK2.6‐2C with mBBr (A), IAM (B), sulfonic acid (C), or glutathione group (D). MS/MS ions used for peptides identification were labeled.
Figure 5Detection of peptides containing mBBr‐labeled tyrosine residues by LC‐MS/MS. (A) MS/MS spectrum of a peptide‐containing mBBr‐labeled Y51 of BnSnRK2.6‐2C. MS/MS ions used for peptides identification were labeled. (B) Proportion of peptides with mBBr‐labeled tyrosine and cysteine residues to total peptides detected in different redox treatments. Four replicates were used for statistical analysis, Duncan method was used in one‐way ANOVA analysis, P < 0.05, and standard errors were indicated by error bars.
Figure 6Simplified diagram depicting how redox regulation of BnSnRK2.6‐2C may affect guard cell processes leading to stomatal closure. Direct and indirect processes are indicated by solid and dashed lines, respectively.